Editor's Note: Any reference to TheStreet Ratings and its underlying recommendation does not reflect the opinion of TheStreet, Inc. or any of its contributors including Jim Cramer or Stephanie Link. Two out of the three major indices are trading up today with the Dow Jones Industrial Average ( ^DJI) trading up 8 points (0.0%) at 16,964 as of Wednesday, July 2, 2014, 12:55 PM ET. The NYSE advances/declines ratio sits at 1,180 issues advancing vs. 1,847 declining with 143 unchanged. The Health Services industry currently sits up 0.3% versus the S&P 500, which is unchanged. Top gainers within the industry include Abbott Laboratories ( ABT), up 1.3%, ResMed ( RMD), up 1.2%, Fresenius Medical Care AG & Co. KGaA ( FMS), up 0.8%, WellPoint ( WLP), up 0.7% and Aetna ( AET), up 0.6%. TheStreet would like to highlight 3 stocks pushing the industry lower today: 3. Grifols ( GRFS) is one of the companies pushing the Health Services industry lower today. As of noon trading, Grifols is down $0.23 (-0.5%) to $44.24 on light volume. Thus far, 149,560 shares of Grifols exchanged hands as compared to its average daily volume of 684,700 shares. The stock has ranged in price between $44.07-$44.64 after having opened the day at $44.64 as compared to the previous trading day's close of $44.47. Grifols, S.A., a specialty biopharmaceutical company, develops, manufactures, and distributes a range of plasma derivative products primarily in the European Union, Spain, the United States, Canada, and internationally. Grifols has a market cap of $15.1 billion and is part of the health care sector. Shares are up 23.1% year-to-date as of the close of trading on Tuesday. Currently there are 3 analysts that rate Grifols a buy, no analysts rate it a sell, and none rate it a hold. TheStreet Ratings rates Grifols as a hold. The company's strengths can be seen in multiple areas, such as its solid stock price performance, impressive record of earnings per share growth and compelling growth in net income. However, as a counter to these strengths, we find that the company has favored debt over equity in the management of its balance sheet. Get the full Grifols Ratings Report now. STOCKS TO BUY: TheStreet Quant Ratings has identified a handful of stocks that can potentially TRIPLE in the next 12 months. Learn more.